EPS for Abeona Therapeutics Inc. (ABEO) Expected At $-0.13

March 19, 2018 - By Clifton Ray

 EPS for Abeona Therapeutics Inc. (ABEO) Expected At $ 0.13

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.13 EPS on March, 30.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.13 EPS previously, Abeona Therapeutics Inc.’s analysts see 0.00 % EPS growth. The stock decreased 0.33% or $0.05 during the last trading session, reaching $15.3. About 94,606 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since March 19, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 36 analyst reports since December 16, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, February 7. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Thursday, June 1 by Jefferies. Citigroup initiated the shares of ABEO in report on Tuesday, October 10 with “Buy” rating. Jefferies maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Friday, October 6. Jefferies has “Buy” rating and $27.0 target. Cantor Fitzgerald maintained the stock with “Overweight” rating in Thursday, October 12 report. The firm earned “Buy” rating on Wednesday, November 22 by H.C. Wainwright. As per Monday, September 25, the company rating was maintained by Cantor Fitzgerald. Jefferies maintained the shares of ABEO in report on Tuesday, November 21 with “Buy” rating. The firm has “Buy” rating given on Tuesday, August 8 by Cowen & Co. Maxim Group initiated the shares of ABEO in report on Wednesday, December 16 with “Buy” rating.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $722.57 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.